| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1004207404 |
| P356 | DOI | 10.1186/CC9354 |
| P932 | PMC publication ID | 3220038 |
| P698 | PubMed publication ID | 21118528 |
| P5875 | ResearchGate publication ID | 49645991 |
| P2093 | author name string | Yan Zhang | |
| Ying Zhou | |||
| Jinbao Li | |||
| Jingsheng Lou | |||
| Keming Zhu | |||
| Lulong Bo | |||
| Xiaojian Wan | |||
| Xiaoming Deng | |||
| Zailong Cai | |||
| P2860 | cites work | Silencing of fas-associated death domain protects mice from septic lung inflammation and apoptosis | Q45883057 |
| Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages | Q47231413 | ||
| Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation | Q47581760 | ||
| B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. | Q47926434 | ||
| Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro | Q56902028 | ||
| Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients | Q56906281 | ||
| PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis | Q57083098 | ||
| Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis | Q62817712 | ||
| Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans | Q73896312 | ||
| B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts | Q79287397 | ||
| Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis | Q79755036 | ||
| Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis | Q84255932 | ||
| Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production | Q24292957 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis | Q28585138 | ||
| Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity | Q33186765 | ||
| IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. | Q34039180 | ||
| IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. | Q34120958 | ||
| Dysregulation of in vitro cytokine production by monocytes during sepsis | Q34211246 | ||
| PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis | Q34605998 | ||
| PD-1 on dendritic cells impedes innate immunity against bacterial infection | Q34606110 | ||
| The enigma of sepsis | Q35202458 | ||
| The contribution of CD4+ CD25+ T-regulatory-cells to immune suppression in sepsis | Q35652637 | ||
| In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice | Q35848213 | ||
| Leukocyte apoptosis and its significance in sepsis and shock | Q36092243 | ||
| Novel therapies for sepsis: a review | Q36095713 | ||
| The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum | Q36497473 | ||
| Caspase inhibitors promote alternative cell death pathways | Q36633894 | ||
| The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection | Q36737159 | ||
| Apoptosis in sepsis: mechanisms, clinical impact and potential therapeutic targets. | Q37239822 | ||
| Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. | Q37256978 | ||
| Sepsis, apoptosis and complement | Q37291833 | ||
| The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients | Q37309561 | ||
| Lymphocytes, apoptosis and sepsis: making the jump from mice to humans | Q37392947 | ||
| Monocyte deactivation--rationale for a new therapeutic strategy in sepsis | Q41219022 | ||
| The sepsis seesaw: tilting toward immunosuppression | Q42035078 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | R220 | |
| P577 | publication date | 2010-11-30 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction | |
| P478 | volume | 14 |
| Q37604045 | A Novel Role for Programmed Cell Death Receptor Ligand-1 (PD-L1) in Sepsis-Induced Intestinal Dysfunction |
| Q49375374 | A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis. |
| Q93091720 | A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction |
| Q36633756 | A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis |
| Q36119404 | Acute-Phase Deaths from Murine Polymicrobial Sepsis Are Characterized by Innate Immune Suppression Rather Than Exhaustion |
| Q34666178 | Adoptive transfer of bone marrow-derived dendritic cells decreases inhibitory and regulatory T-cell differentiation and improves survival in murine polymicrobial sepsis |
| Q47310265 | Advances in the understanding and treatment of sepsis-induced immunosuppression. |
| Q35546243 | Alterations in antigen-specific naive CD4 T cell precursors after sepsis impairs their responsiveness to pathogen challenge. |
| Q47139345 | Analysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonates. |
| Q60912221 | Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs) |
| Q40404109 | Anti-PD-L1 peptide improves survival in sepsis |
| Q38998292 | Apoptosis-induced lymphopenia in sepsis and other severe injuries |
| Q49751937 | Autophagy: A Potential Therapeutic Target for Reversing Sepsis-Induced Immunosuppression |
| Q40763516 | BTLA as a biomarker and mediator of sepsis-induced immunosuppression |
| Q41897433 | BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction |
| Q34270607 | Baicalin improves survival in a murine model of polymicrobial sepsis via suppressing inflammatory response and lymphocyte apoptosis |
| Q36829883 | Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis |
| Q33660802 | Blockade of ICAM-1 improves the outcome of polymicrobial sepsis via modulating neutrophil migration and reversing immunosuppression |
| Q36997987 | Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis |
| Q26796132 | CD1d- and MR1-Restricted T Cells in Sepsis |
| Q98177684 | CD4 T Cell Responses and the Sepsis-Induced Immunoparalysis State |
| Q89534167 | Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis |
| Q61805074 | Commentary: Precision Immunotherapy for Sepsis |
| Q36919711 | Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease |
| Q90523433 | Crosstalk between Dendritic Cells and Immune Modulatory Agents against Sepsis |
| Q87250173 | Decreased PD-1/PD-L1 Expression Is Associated with the Reduction in Mucosal Immunoglobulin A in Mice with Intestinal Ischemia Reperfusion |
| Q38929971 | Emerging infection and sepsis biomarkers: will they change current therapies? |
| Q41592753 | Escherichia coli-induced immune paralysis is not exacerbated during chronic filarial infection |
| Q47226688 | Ex vivo Stimulation of Lymphocytes with IL-10 Mimics Sepsis-Induced Intrinsic T-Cell Alterations |
| Q87642469 | Expression of programmed death-1 and its ligands in the liver of biliary atresia |
| Q40601111 | Flt3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in a Murine Model of Burn Wound Sepsis |
| Q49977565 | Frontline Science: Anti-PD-L1 protects against infection with common bacterial pathogens after burn injury |
| Q28658232 | Galectin-9 prolongs the survival of septic mice by expanding Tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages |
| Q36133114 | Global analysis of differential gene expression related to long-term sperm storage in oviduct of Chinese Soft-Shelled Turtle Pelodiscus sinensis |
| Q40164934 | Glutamine Administration in Early or Late Septic Phase Downregulates Lymphocyte PD-1/PD-L1 Expression and the Inflammatory Response in Mice With Polymicrobial Sepsis |
| Q34844755 | Helminths and their implication in sepsis - a new branch of their immunomodulatory behaviour? |
| Q37624125 | Hydrogen sulfide [corrected] increases survival during sepsis: protective effect of CHOP inhibition |
| Q58572827 | IL-17RA-Signaling Modulates CD8+ T Cell Survival and Exhaustion During Infection |
| Q60313561 | Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients |
| Q90053719 | Immune Response to Mycobacterium tuberculosis: A Narrative Review |
| Q90429204 | Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab |
| Q53685582 | Immune checkpoint receptors: homeostatic regulators of immunity. |
| Q38217723 | Immunomodulatory adjuvant therapy in severe community-acquired pneumonia |
| Q38152236 | Immunopathogenesis of abdominal sepsis |
| Q27320494 | Immunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell function |
| Q37233354 | Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach |
| Q38836832 | Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression |
| Q34341378 | Impact of sepsis on CD4 T cell immunity |
| Q92069830 | Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q27691996 | Is boosting the immune system in sepsis appropriate? |
| Q37238322 | Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. |
| Q64094873 | Late immune consequences of combat trauma: a review of trauma-related immune dysfunction and potential therapies |
| Q91603708 | Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis |
| Q36882441 | Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study |
| Q33909697 | Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis |
| Q49892780 | Mycophenolate Mofetil Protects Septic Mice via the Dual Inhibition of Inflammatory Cytokines and PD-1. |
| Q34441546 | Neutralisation of peritoneal IL-17A markedly improves the prognosis of severe septic mice by decreasing neutrophil infiltration and proinflammatory cytokines |
| Q35603467 | Notch Signaling Pathway Was Involved in Regulating Programmed Cell Death 1 Expression during Sepsis-Induced Immunosuppression |
| Q58764867 | Oxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis |
| Q35936041 | PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis |
| Q47755022 | PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1α. |
| Q37351521 | PD-L1 blockade attenuated sepsis-induced liver injury in a mouse cecal ligation and puncture model. |
| Q39614582 | PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes |
| Q56891292 | PD-L1, TIM-3, and CTLA-4 blockade fail to promote resistance to secondary infection with virulent strains of |
| Q89338776 | Partial Depletion of Regulatory T Cells Enhances Host Inflammatory Response Against Acute Pseudomonas aeruginosa Infection After Sepsis |
| Q90703154 | Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis |
| Q35184876 | Persistent lymphopenia after diagnosis of sepsis predicts mortality. |
| Q90074305 | Pharmacokinetics, Pharmacodynamics and Safety of Nivolumab in Patients With Sepsis-induced immunosuppression: A multicenter, open-label phase 1/2 study |
| Q47102338 | Potential Immunotherapeutics for Immunosuppression in Sepsis |
| Q57160595 | Precision Immunotherapy for Sepsis |
| Q58787789 | Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis |
| Q29994668 | Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
| Q34173755 | Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes |
| Q38924981 | Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions |
| Q35559497 | Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. |
| Q38890353 | Role of cellular events in the pathophysiology of sepsis |
| Q34177314 | Role of circulating lymphocytes in patients with sepsis |
| Q36412089 | Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis |
| Q59136322 | Sepsis and Nosocomial Infection: Patient Characteristics, Mechanisms, and Modulation |
| Q40625575 | Sepsis in PD-1 light. |
| Q59800492 | Sepsis-Induced Immunosuppression in Neonates |
| Q33828888 | Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy |
| Q37678563 | Sepsis-induced potentiation of peritoneal macrophage migration is mitigated by programmed cell death receptor-1 gene deficiency. |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q39172565 | Serum sPD-L1, Upregulated in Sepsis, May Reflect Disease Severity and Clinical Outcomes in Septic Patients |
| Q39457700 | Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. |
| Q36240333 | Soluble B and T Lymphocyte Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an Increased Risk of Mortality |
| Q28537588 | Soluble tumor necrosis factor related apoptosis inducing ligand level as a predictor of severity of sepsis and the risk of mortality in septic patients |
| Q36480729 | T cells from patients with Candida sepsis display a suppressive immunophenotype |
| Q47150101 | Targeting Immune Cell Checkpoints during Sepsis |
| Q33749945 | Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis |
| Q55419461 | The Central Role of the Inflammatory Response in Understanding the Heterogeneity of Sepsis-3. |
| Q91711995 | The Role of PD-1 in Acute and Chronic Infection |
| Q37563023 | The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? |
| Q55504414 | The human blood DNA methylome identifies crucial role of β-catenin in the pathogenesis of Kawasaki disease. |
| Q37686624 | The new normal: immunomodulatory agents against sepsis immune suppression |
| Q27302768 | Tolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine Splenocytes |
| Q64084951 | Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis |
| Q35611631 | Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. |
| Q35567048 | Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients |
| Q60959341 | Using the Spleen as an Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with -PD-L1 |
| Q30578885 | Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans |
| Q38139929 | When host defense goes awry: Modeling sepsis-induced immunosuppression |
Search more.